Methods: In this paper, a brief review of the literature on JAK/STAT pathway dysregulation in CTCL is provided, highlighting both clinical and preclinical studies involving JAK inhibitors and other agents that target this pathway. The gene discussed is SOAT1; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.